Virotherapy News and Research RSS Feed - Virotherapy News and Research

Virotherapy is treatment using a virus that has been changed in the laboratory to find and destroy cancer cells without harming healthy cells. It is a type of targeted therapy. Also called oncolytic virotherapy, oncolytic virus therapy, and viral therapy.
Transgene welcomes SillaJen’s intention to acquire Jennerex

Transgene welcomes SillaJen’s intention to acquire Jennerex

Transgene SA (Paris:TNG) said today that it welcomed the announcement by SillaJen, Inc. of its intention to acquire Jennerex, Inc. and has consequently given its consent to the definitive merger agreement. [More]

Viralytics releases financial results for 2013

Viralytics Limited (ASX:VLA, OTCQX:VRACY) has released its financial results for the year ended 30 June 2013. [More]
Recombinant Newcastle disease virus kills all kinds of prostate cancer cells

Recombinant Newcastle disease virus kills all kinds of prostate cancer cells

A recombinant Newcastle disease virus kills all kinds of prostate cancer cells, including hormone resistant cells, but leaves normal cells unscathed, according to a paper published online ahead of print in the Journal of Virology. [More]
Natural killer cell response detrimental to glioblastoma virotherapy

Natural killer cell response detrimental to glioblastoma virotherapy

For the first time, researchers have demonstrated that the response of natural killer (NK) cells is detrimental to glioblastoma virotherapy, a novel way of treating malignant brain cancer by injecting a virus into the tumor. [More]
Cancer therapy with common cold virus

Cancer therapy with common cold virus

Common viruses have become the latest weapon against cancer. There is the case of the eight-year-old African boy diagnosed with Burkitt's lymphoma at a Ugandan health clinic. He was exposed to the measles virus and in the next few weeks his tumour regressed completely and he entered remission. But only relatively recently have scientists clinically examined the interaction between viruses and cancers in the growing area of oncolytic virotherapy. [More]
Advaxis, Vibalogics to develop storage-stable formulation for live Listeria vaccines

Advaxis, Vibalogics to develop storage-stable formulation for live Listeria vaccines

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company and Vibalogics GmbH, a German biologics manufacturing company, have agreed to co-develop a room temperature stable, processing technology for live vaccines originally engineered for Advaxis. [More]
Scientists shrink distant sarcomas with genetically reprogrammed herpes virus and anti-vascular drug

Scientists shrink distant sarcomas with genetically reprogrammed herpes virus and anti-vascular drug

Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice – still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy. [More]

Scientists use genetically reprogrammed herpes virus to shrink distant sarcomas

Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice - still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy. [More]
South Dakota State University mathematicians design mathematical models to treat cancer

South Dakota State University mathematicians design mathematical models to treat cancer

South Dakota State University mathematicians are helping doctors of the Mayo Clinic build mathematical models to fine-tune an innovative strategy to treat cancer. [More]

Combining antiangiogenic cancer therapy with oncolytic virotherapy leads to regression of tumors

Oncolytics Biotech Inc. announced today that a paper entitled "Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice," co-senior authored by Dr. Richard Vile of the Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA, and Dr. Kevin Harrington of the Institute of Cancer Research, London, UK, was published in the online version of the Journal of Clinical Investigation on April 1, 2010. [More]
Global market for oncology drugs is forecast to reach $80 billion by 2050

Global market for oncology drugs is forecast to reach $80 billion by 2050

New Medicine's Oncology KnowledgeBASE (nm/OK) residing at http://nmok.net became available on the Internet 10 years ago and, since then, the oncology field has evolved into one of the most challenging, complex and promising drug development sectors, both in terms of its potential contribution to medicine and to its market opportunities. [More]
Trial of new ‘combo’ treatment for hepatitis C

Trial of new ‘combo’ treatment for hepatitis C

In a multi-center trial led by a Saint Louis University researcher, investigators found that a new combination therapy of daily consensus interferon and ribavirin helps some hepatitis C patients who have not responded to previous treatment. [More]
Tamed virus wipes out cancer safely

Tamed virus wipes out cancer safely

Cancer Research UK scientists have tamed a virus so that it attacks and destroys cancer cells but does not harm healthy cells, according to a paper published in PLoS Pathogens, today. [More]
Cimzia approved in U.S. for rheumatoid arthritis

Cimzia approved in U.S. for rheumatoid arthritis

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). [More]
Virotherapy treatment kills prostate cancer cells

Virotherapy treatment kills prostate cancer cells

A new study appearing in The Prostate has found that certain measles virus vaccine strain derivatives, including a strain known as MV-CEA, may prove to be an effective treatment for patients with advanced prostate cancer. [More]
May hepatic granulomas be part of the histological spectrum of chronic hepatitis C?

May hepatic granulomas be part of the histological spectrum of chronic hepatitis C?

While older large series of patients with hepatic granulomas have found sarcoidosis and tuberculosis to be the most common causes of hepatic granulomas, recent works have noted some patients with chronic hepatic C and hepatic granulomas and no other obvious associations. [More]

Low-dose peginterferon used for hepatitis C doesn't work

An NIH funded multi-center clinical trial found no benefit from "maintenance therapy," low-dose peginterferon used for hepatitis C patients who have not responded to an initial round of treatment. [More]
Asthma risk increases in children treated for HIV

Asthma risk increases in children treated for HIV

Children whose immune systems rebound after treatment with potent anti-viral drugs for HIV infection face an increased risk of developing asthma, said a federally funded consortium of researchers led by those from Baylor College of Medicine in a report that appears online in the Journal of Allergy and Clinical Immunology. [More]

Technique for analyzing the function of microRNAs wins Barenholz Prize for Hebrew University student

A unique technique for analyzing the function of microRNAs developed by a Hebrew University of Jerusalem doctoral student has led to the discovery of a new mechanism by which viruses evade the human immune system. This discovery has important implications for human intervention in the battle between viruses and humans. [More]

Peregrine Pharmaceuticals awarded two new U.S. patents for targeted anti-aminophospholipid agents

Peregrine Pharmaceuticals, Inc. today reported the issuance of two U.S. patents that significantly broaden the company's intellectual property leadership in the field of targeted anti-aminophospholipid agents. [More]